Open Label Phase I Trial in Healthy Chinese Male and Female Volunteers to Investigate Pharmacokinetics and Pharmacodynamics of Idarucizumab to Reverse Dabigatran Anticoagulant Activity

Trial Profile

Open Label Phase I Trial in Healthy Chinese Male and Female Volunteers to Investigate Pharmacokinetics and Pharmacodynamics of Idarucizumab to Reverse Dabigatran Anticoagulant Activity

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Idarucizumab (Primary) ; Dabigatran etexilate
  • Indications Blood coagulation disorders
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 May 2017 Status changed from not yet recruiting to recruiting.
    • 04 May 2017 Planned End Date changed from 20 Aug 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top